DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention
of colorectal adenomatous polyps. N Engl J Med, 2006,
355:885–895.
Arehart E, Stitham J, Asselbergs FW, et al. Acceleration of cardiovascular
disease by a dysfunctional prostacyclin receptor
mutation: Potential implications for cyclooxygenase-2 inhibition.
Circ Res, 2008, 102:986–993.
Ballou LR, Botting RM, Goorha S, et al. Nociception in
cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci
U S A, 2000, 97:10272–10276.
Barbanoj, MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics
of dexketoprofen. Clin Pharmacokinet, 2001, 40:245–262.
Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of
rofecoxib for the chemoprevention of colorectal adenomas.
Gastroenterology, 2006, 131:1674–1682.
Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events
associated with rofecoxib: Final analysis of the APPROVe
trial. Lancet, 2008, 372:1756–1764.
Baumer JH, Love SJ, Gupta A, et al. Salicylate for the treatment
of Kawasaki disease in children. Cochrane Database Syst Rev,
2006, (4):CD004175.
Becker MA, Schumacher HR Jr, Wortmann RL, et al.
Febuxostat, a novel nonpurine selective inhibitor of xanthine
oxidase: A twenty-eight-day, multicenter, phase II, randomized,
double-blind, placebo-controlled, dose-response clinical
trial examining safety and efficacy in patients with gout.
Arthritis Rheum, 2005a, 52:916–923.
Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat
compared with allopurinol in patients with hyperuricemia and
gout. N Engl J Med, 2005b, 353:2450–2461.
Bennett A. Overview of nimesulide. Rheumatology, 1999,
38(suppl):1–3.
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy
and safety analysis of the Adenoma Prevention with Celecoxib
Trial. Cancer Prev Res (Phila Pa), 2009, 2:310–321.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in patients
with rheumatoid arthritis. VIGOR Study Group. N Engl J Med,
2000, 343:1520–1528, 2 p following 1528.
Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant
urate oxidase) for the management of hyperuricemia in
patients with cancer: Report of an international compassionate
use study. Cancer, 2003, 98:1048–1054.
Boutaud O, Aronoff DM, Richardson JH, et al. Determinants of
the cellular specificity of acetaminophen as an inhibitor of
prostaglandin H(2) synthases. Proc Natl Acad Sci U S A, 2002,
99:7130–7135.
Brennan FM, McInnes IB. Evidence that cytokines play a role in
rheumatoid arthritis. J Clin Invest, 2008, 118:3537–3545.
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events
associated with rofecoxib in a colorectal adenoma chemoprevention
trial. N Engl J Med, 2005, 352:1092–1102.
Brogden RN, Heel RC, Speight TM, Avery GS. Fenbufen: A
review of its pharmacological properties and therapeutic use in
rheumatic diseases and acute pain. Drugs, 1981, 21:1–22.
Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors:
Similarities and differences. Scand J Rheumatol, 2004, 33:1–6.
Buckley MM, Brogden RN. Ketorolac. A review of its pharmacodynamic
and pharmacokinetic properties, and therapeutic
potential. Drugs, 1990, 39:86–109.
Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes
with etoricoxib and diclofenac in patients with osteoarthritis
and rheumatoid arthritis in the Multinational Etoricoxib and
Diclofenac Arthritis Long-term (MEDAL) programme: A randomised
comparison. Lancet, 2006, 368: 1771–1781.
Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic
interaction of naproxen with low-dose aspirin in healthy subjects.
J Am Coll Cardiol, 2005, 45:1295–1301.
Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of
specific inhibition of cyclooxygenase-2 on sodium balance,
hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp
Ther, 1999, 289:735–741.
Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase
inhibitors and the antiplatelet effects of aspirin. N Engl J Med,
2001, 345:1809–1817.
Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a
cyclooxygenase-1 variant inhibited by acetaminophen and
other analgesic/antipyretic drugs: Cloning, structure, and
expression. Proc Natl Acad Sci U S A, 2002, 99:13926–13931.
Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the
cardiovascular response to thromboxane A2. Science, 2002,
296:539–541.
Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal
prostaglandin E synthase-1, and cardiovascular function. J Clin
Invest, 2006, 116:1391–1399.
Cieslik K, Zhu Y, Wu KK. Salicylate suppresses macrophage
nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by
inhibiting CCAAT/enhancer-binding protein-beta binding via
a common signaling pathway. J Biol Chem, 2002, 277:
49304–49310.
Clyman RI, Hardy P, Waleh N, et al. Cyclooxygenase-2 plays a
significant role in regulating the tone of the fetal lamb ductus
arteriosus. Am J Physiol, 1999, 276(3 pt 2):R913–R921.
Coggins KG, Latour A, Nguyen MS, et al. Metabolism of PGE2
by prostaglandin dehydrogenase is essential for remodeling
the ductus arteriosus. Nat Med, 2002, 8:91–92.
Cruz-Correa M, Hylind LM, Romans KE, et al. Long-term treatment
with sulindac in familial adenomatous polyposis: A
prospective cohort study. Gastroenterology, 2002, 122:
641–645.
Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2
inhibitor use since market release: Nonselective diffusion
of a selectively cost-effective innovation. Arch Intern
Med, 2005, 165:171–177.
Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective
serotonin reuptake inhibitors and risk of upper gastrointestinal
tract bleeding: A population-based cohort study. Arch
Intern Med, 2003, 163:59–64.
Davies NM. Clinical pharmacokinetics of flurbiprofen and its
enantiomers. Clin Pharmacokinet, 1995, 28:100–114.
Davies NM. Clinical pharmacokinetics of ibuprofen. The first
30 years. Clin Pharmacokinet, 1998a, 34:101–154.
Davies NM. Clinical pharmacokinetics of nabumetone. The
dawn of selective cyclo-oxygenase-2 inhibition? Clin
Pharmacokinet, 1997, 33:404–416.
Davies NM. Clinical pharmacokinetics of oxaprozin. Clin
Pharmacokinet, 1998b, 35:425–436.
Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac.
Therapeutic insights and pitfalls. Clin Pharmacokinet, 1997a,
33:184–213.
1001
CHAPTER 34
ANTI-INFLAMMATORY, ANTIPYRETIC, AND ANALGESIC AGENTS; PHARMACOTHERAPY OF GOUT